Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With SOX Versus SOX as Adjuvant Therapy for Patients With Stage pIIIC or dMMR/MSI-H Stage pIIIA/IIIB Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-center, Randomized Controlled Phase II Clinical Trial

NCT07492615 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07492615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With SOX Versus SOX as Adjuvant Therapy for Patients With Stage pIIIC or dMMR/MSI-H Stage pIIIA/IIIB Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-center, Randomized Controlled Phase II Clinical Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 29, 2026
Completion date
February 20, 2033
Enrollment
276 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer or gastroesophageal junction adenocarcinoma